Institution · Top Institute Pharma
Most cited papers from Top Institute Pharma
What are the most cited papers from Top Institute Pharma?
The most cited paper from Top Institute Pharma is "How to Regulate Nonbiological Complex Drugs (NBCD) and Their Follow-on Versions: Points to Consider" (Huub Schellekens, Sven Stegemann, Vera Weinstein et al., 2013), with 121 citations. Next come "The therapeutic equivalence of complex drugs" (111) and "How to screen non-viral gene delivery systems in vitro?" (110).
Showing 30 of 30 papers. Every paper is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | How to Regulate Nonbiological Complex Drugs (NBCD) and Their Follow-on Versions: Points to Consider Huub Schellekens, Sven Stegemann, Vera Weinstein et al. · The AAPS Journal | 25 Sep 2013 | 121 |
| 2 | The therapeutic equivalence of complex drugs Huub Schellekens, Ety Klinger, Stefan Mühlebach et al. · Regulatory Toxicology and Pharmacology | 15 Oct 2010 | 111 |
| 3 | How to screen non-viral gene delivery systems in vitro? Ethlinn V.B. van Gaal, Roel van Eijk, Ronald S. Oosting et al. · Journal of Controlled Release | 10 May 2011 | 110 |
| 4 | The similarity question for biologicals and non-biological complex drugs Daan J.A. Crommelin, Vinod P. Shah, Imre Klebovich et al. · European Journal of Pharmaceutical Sciences | 25 Apr 2015 | 69 |
| 5 | Flow cytometry for rapid size determination and sorting of nucleic acid containing nanoparticles in biological fluids Ethlinn V.B. van Gaal, G. Th. Spierenburg, Wim E. Hennink et al. · Journal of Controlled Release | 23 Sep 2009 | 61 |
| 6 | Different Pharmaceutical Products Need Similar Terminology Daan J.A. Crommelin, Jon S. B. de Vlieger, Vera Weinstein et al. · The AAPS Journal | 25 Sep 2013 | 59 |
| 7 | DNA Nuclear Targeting Sequences for Non-Viral Gene Delivery Ethlinn V.B. van Gaal, Ronald S. Oosting, Roel van Eijk et al. · Pharmaceutical Research | 17 Mar 2011 | 59 |
| 8 | Pharmaceutical sciences in 2020 Daan J.A. Crommelin, Pieter Stolk, Luc Besançon et al. · Nature Reviews Drug Discovery | Feb 2010 | 52 |
| 9 | Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports Kevin C. Klein, Joep H. G. Scholl, Niels S. Vermeer et al. · Drug Safety | 30 Dec 2015 | 37 |
| 10 | Fragment-Based Screening in Tandem with Phenotypic Screening Provides Novel Antiparasitic Hits Antoni R. Blaazer, Kristina Maria Orrling, Anitha Shanmugham et al. · SLAS DISCOVERY | 18 Sep 2014 | 27 |
| 11 | Pharmacometrics as a Discipline Is Entering the “Industrialization” Phase: Standards, Automation, Knowledge Sharing, and Training Are Critical for Future Success Klaus Romero, Brian Corrigan, Christoffer Wenzel Tornøe et al. · The Journal of Clinical Pharmacology | Sep 2010 | 26 |
| 12 | Junk DNA enhances pEI-based non-viral gene delivery Ethlinn V.B. van Gaal, Ronald S. Oosting, Wim E. Hennink et al. · International Journal of Pharmaceutics | 30 Aug 2009 | 24 |
| 13 | ‘Personalised medicine’ through ‘personalised medicines’: Time to integrate advanced, non-invasive imaging approaches and smart drug delivery systems Daan J.A. Crommelin, Gert Storm, Peter R. Luijten · International Journal of Pharmaceutics | 13 Feb 2011 | 24 |
| 14 | Measuring the value of public–private partnerships in the pharmaceutical sciences Tom R. Denee, Arnold Sneekes, Pieter Stolk et al. · Nature Reviews Drug Discovery | 30 Mar 2012 | 21 |
| 15 | Public–private partnerships in translational medicine: Concepts and practical examples Peter R. Luijten, Guus A.M.S. van Dongen, CHRIT T. W. MOONEN et al. · Journal of Controlled Release | 20 Mar 2012 | 16 |
| 16 | Respiratory sensitization: Advances in assessing the risk of respiratory inflammation and irritation Rob J. Vandebriel, Conchita Callant Cransveld, Daan J.A. Crommelin et al. · Toxicology in Vitro | 8 May 2011 | 14 |
| 17 | Diclofenac enhances allergic responses in a mouse peanut allergy model Marianne Bol‐Schoenmakers, Rob Bleumink, Marisa Marcondes Rezende et al. · Clinical & Experimental Allergy | 16 Aug 2010 | 14 |
| 18 | The Pharmaceutical Sciences in 2020: Report of a Conference Organized by the Board of Pharmaceutical Sciences of the International Pharmaceutical Federation (FIP) Vinod P. Shah, Luc Besançon, Pieter Stolk et al. · Pharmaceutical Research | 26 Jan 2010 | 12 |
| 19 | The European lead factory—an experiment in collaborative drug discovery Hugh Laverty, Kristina Maria Orrling, Fabrizio Giordanetto et al. · JOURNAL OF MEDICINES DEVELOPMENT SCIENCES | 20 Jul 2015 | 11 |
| 20 | Non-biological complex drugs (NBCDs) and their follow-on versions: time for an editorial section Jon SB de Vlieger, Stefan Mühlebach, Vinod P. Shah et al. · Generics and Biosimilars Initiative Journal | 15 Dec 2015 | 10 |
| 21 | Introduction: Defining the Position of Non-Biological Complex Drugs Daan J.A. Crommelin, Jon S. B. de Vlieger, Stefan Mühlebach · AAPS advances in the pharmaceutical sciences series | 2015 | 9 |
| 22 | Oral Exposure to Drugs with Immune-Adjuvant Potential Induces Hypersensitivity Responses to the Reporter Antigen TNP-OVA Lydia M. Kwast, Daniëlle Fiechter, Ine Hassing et al. · Toxicological Sciences | 14 Mar 2011 | 8 |
| 23 | Roles and strategies for health foundations in public–private partnerships Remco L. de Vrueh, Waseem Awad, Anne Stolk et al. · Nature Reviews Drug Discovery | 30 May 2014 | 6 |
| 24 | Classification of Recombinant Biologics in the EU: Divergence Between National Pharmacovigilance Centers Kevin C. Klein, Marie L. De Bruin, André W. Broekmans et al. · BioDrugs | 30 Nov 2015 | 5 |
| 25 | Oral exposure to immunostimulating drugs results in early changes in innate immune parameters in the spleen Lydia M. Kwast, Daniëlle Fiechter, Laura J. W. Kruijssen et al. · Journal of Immunotoxicology | 4 Apr 2016 | 4 |
| 26 | Immune responses induced by diclofenac or carbamazepine in an oral exposure model using TNP-Ficoll as reporter antigen Lydia M. Kwast, Tetsuo Aida, Daniëlle Fiechter et al. · Journal of Immunotoxicology | Nov 2016 | 1 |
| 27 | Epilogue: What Did We Learn? What Can We Expect in the Future? Concluding Remarks and Outstanding Issues Daan J.A. Crommelin, Jon S. B. de Vlieger · AAPS advances in the pharmaceutical sciences series | 2015 | 1 |
| 28 | The EUFEPS workshop on institutional peer review “The ultimate tool to advance the pharmaceutical sciences?” Daan J.A. Crommelin, Ole J. Bjerrum · European Journal of Pharmaceutical Sciences | 20 Aug 2008 | 1 |
| 29 | Nanotechnological approaches for targeted drug delivery: hype or hope? Daan J.A. Crommelin · New Biotechnology | 27 Aug 2009 | 0 |
| 30 | Effects of atypical antipsychotic Olanzapine on feeding behavior and energy metabolism M. C. de RUITER, Sjoerd A.A. van den Berg, Hanno Pijl et al. · Appetite | Jun 2009 | 0 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.